Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib (JAK1 Inhibitor):  Atopic Dermatitis 
  • Braftovi® (encorafinib)  + Erbitux® (cetuximab):  1st line BRAF-mutant Metastatic Colorectal Cancer 
  • Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab):  BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
  • COVID-19 Vaccine:  COVID-19 Infection (in collaboration with BioNTech)
  • Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX):  Hemophilia
  • Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy):  Duchenne Muscular Dystrophy
  • Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII):  Hemophilia
  • Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor):  Hemophilia
  • Prophylactic Vaccine:  Clostridioides difficile infection
  • Prophylactic Vaccine:  Invasive and Non-Invasive Pneumococcal infections (adult, pediatric) 
  • Prophylactic Vaccine:  Meningococcal Infections (adolescent and young adults)
  • Prophylactic Vaccine:  Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
  • Relugolix combination: Uterine Fibroids, Endometriosis
  • Ritlecitinib (JAK3/TEC Inhibitor):  Alopecia Areata 
  • Sasanlimab (PF-06801591) + BCG:  Non-Muscle-Invasive Bladder Cancer
  • Somatrogon (PF-06836922):  Growth Hormone Deficiency (adult, pediatric)
  • Talzenna® (talazoparib) + Xtandi® (enzalutamide):  1st Line Metastatic Castration-Resistant Prostate Cancer 
  • Tanezumab:  Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
  • Xtandi® (enzalutamide):  Non-metastatic High-Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of May 4, 2021

  • Discovery Projects
  • Phase 1
    30
  • Phase 2
    38
  • Phase 3
    22
  • Registration
    10
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High-Risk Castration Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor and anti PD-1
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
Project advanced
Phase 3 Product Enhancement Small Molecule
Braftovi (encorafinib) + Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor and anti EGFR
Go to clinical trial
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/CMP-001 for Head and Neck Cancer (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor
1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer Phase 2 Product Enhancement Small Molecule
Elranatamab
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Multiple Myeloma (Biologic)
Project advanced
Phase 2 New Molecular Entity Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
CD137 Agonist
Combo w/Kite Pharma'sYescarta® (axicabtagene ciloleucel)forCancer(Biologic) Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
HER2 Antibody Drug Conjugate
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06936308
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Multiple Cancers Phase 1 New Molecular Entity Small Molecule
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule